COMP <GO>
INSP vs XRAY // PIOTROSKI F-SCORE QUALITY
Inspire Medical Systems Inc. (NYSE) VS. DENTSPLY SIRONA Inc. (NASDAQ) • 15-METRIC TALLY: INSP 8
— XRAY 3
▲ PIOTROSKI F-SCORE QUALITY LEADER: INSP
LAST: $71.18 (+0.30%) • MKT CAP: $2.06B
piotroski-score
7/9
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
piotroski-score
6/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSP VS. XRAY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSP | XRAY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.40% | 50.00% | +35.40 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | -11.00% | +17.00 | INSP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.81% | 12.27% | -8.46 | XRAY | /fcf-yield <GO> |
| Operating Margin | 5.60% | -11.50% | +17.10 | INSP | /operating-margins <GO> |
| Net Profit Margin | 15.90% | -16.20% | +32.10 | INSP | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | -3.00% | +16.60 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 6.68% | -6.68 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.40 | 0.45 | +10.95 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 6/9 | +1.00 | INSP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.4 | 55.1 | -9.72 | XRAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.06B | $1.92B | $142.0M | INSP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSP REV | XRAY REV | INSP GROSS % | XRAY GROSS % | INSP FCF | XRAY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $912.0M | $3.68B | 85.4% | 50.0% | $78.5M | $235.0M |
| FY 2024 | $802.8M | $3.79B | 84.7% | 51.6% | $91.1M | $461.0M |
| FY 2023 | $624.8M | $3.96B | — | — | $24.7M | $377.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSP // BETA —
XRAY // BETA —